Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1Phase 1 1

Status

Active not recruiting 4Recruiting 2

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 6

Conditions

Breast Neoplasms 3099Neoplasms 2443Carcinoma, Non-Small-Cell Lung 1867Prostatic Neoplasms 1619Colorectal Neoplasms 1426Lung Neoplasms 1295Multiple Myeloma 929Neoplasm Metastasis 920Leukemia, Myeloid, Acute 874Pancreatic Neoplasms 848Ovarian Neoplasms 799Melanoma 784Carcinoma, Hepatocellular 737Stomach Neoplasms 639Brain Neoplasms 636Recurrence 633Squamous Cell Carcinoma of Head and Neck 632Head and Neck Neoplasms 609Glioblastoma 567Lymphoma 540Uterine Cervical Neoplasms 539Triple Negative Breast Neoplasms 505Precursor Cell Lymphoblastic Leukemia-Lymphoma 499Carcinoma, Renal Cell 499Hematologic Neoplasms 463Urinary Bladder Neoplasms 459Endometrial Neoplasms 459Colonic Neoplasms 442Lymphoma, Non-Hodgkin 436Sarcoma 434

Interventions

sipuleucel-T 2enzalutamide 2gallium 68 PSMA-11 1Vancomycin 1Metronidazole 1Docetaxel 1Ciprofloxacin 1Amoxicillin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Metastatic Castration-Resistant Prostate Cancer (mCRPC) × 1 year × Clear all
NCT05806814 2026-05-27

OU-SCC-EXCITE

University of Oklahoma

Phase 1 Active not recruiting
15 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT05658003 2026-03-23

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Novartis

Phase 2 Active not recruiting
63 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT05670106 2026-02-13

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC

Novartis

Phase 2 Active not recruiting
62 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06126731 2025-11-24

Combination Study of Antibiotics With Enzalutamide (PROMIZE)

Institute of Cancer Research, United Kingdom

Phase 1/2 Recruiting
39 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06134232 2025-08-27

ProvONE

Dendreon

Phase 2 Recruiting
400 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT04015622 2025-08-20

PROTRACT

British Columbia Cancer Agency

Phase 2 Active not recruiting
100 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡